P269: Penetrance and phenotypic findings of cardiovascular variants identified from biobank, secondary, and unanticipated findings in an adult clinical cohort

As diagnostic genetic tests are more widespread, both secondary and unanticipated findings are being increasingly identified. Similarly, research biobanks are becoming more prevalent, with one goal being to return actionable genetic findings. In December 2023, UCLA Health launched the ATLAS Genetic Screening Program (GSP), which aims to return actionable findings. As a result, clinics will see an increase in the evaluation and management of secondary findings. To provide more accurate counseling on disease risks, an understanding of the penetrance associated with such findings is essential.